Meeting Description

This meeting collaboration between the Association for Cancer Immunotherapy CIMT and the Champalimaud Foundation will address promising paths towards effective cellular treatment modalities for patients with solid cancer and discuss the boundaries of synthetically engineered immune cells. The meeting will also discuss the innovation gap between academic and small biotech driven research, and the challenges of safe, biologically, and clinically relevant phase I / II clinical trials. 

Description

Nuno Prego Ramos, co-founder and CEO of CellmAbs, will share the journey of CellmAbs, from it's early days starting with an initial technology from NOVA University to becoming a pioneering force in cancer therapy innovation.

In this talk, we will hear about the strategic decisions, challenges and breakthroughs that propelled the company to its selling the assets to the pharmaceutical giant, BioNTech.

“When I explain to my friends and family the rigorous regulations in place to ensure ethical treatment of experimental animals, they seem surprised.
 
It is important that people know that researchers that use animals are obliged to have appropriate qualifications and training. That scientific projects are evaluated to ensure that the use of animals is needed, beneficial and that no unnecessary harm is inflicted. And that the highest standards of housing conditions must be provided by the facilities where animals are housed.
 

A study published in mid-April in the journal Nature Communications by Leopoldo Petreanu and his team, from the Cortical Circuits lab at Champalimaud Research, concludes that sensory processing by the visual cortex’s is not purely visual. More to the point, the study shows that, right from the early stages of sensory processing, the visual cortex integrates information from other sensory modalities, such as sounds.

Part I of the series of Ar Events under the motto “Roots of AI” was about the past – the history of artificial intelligence". Now, the “Creative Directors” and the invited speakers of Part II of the series, which took place at the Champalimaud Foundation (CF) last month, undertook to discuss the now of AI, sharing their views on the pros and cons of the technology. Part III (the last event of the series) will take place on May 7th and will deal with the future of AI.